ArticleBMC complementary medicine and therapies2026
Nano-formulated pomegranate extracts with dual cytotoxic and antimicrobial activity: molecular docking and mechanistic insights into leukemia cell targeting.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting CDK-2 With Novel Indole-Pyrazole Hybrids: Discovery of Potent Anticancer Agents Supported by Mechanistic and In Silico Studies.Drug development research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ethnopharmacological relevancePunica granatum (pomegranate) peel is traditionally used for its antimicrobial and health-promoting properties in several cultures. Rich in polyphenols, the peel has attracted interest for its potential applications in treating infections and cancer, particularly in integrative approaches for immunocompromised patients. MATERIALS AND
methodsPomegranate peel extracts were prepared using solvents of increasing polarity, with emphasis on the ethyl acetate fraction (PPE-EA). A nano-formulated version (n-PPE-EA) was developed using a standard nano-encapsulation technique. Cytotoxic activity was evaluated in THP-1 human leukemia cells using MTT assay, flow cytometry, and biochemical analyses. Antimicrobial activity was assessed against Streptococcus pyogenes via agar diffusion. Gene expression of BCL2, PI3K, and CDK8 was measured to elucidate mechanisms of action.
resultsAmong all tested extracts, PPE-EA showed the strongest dual activity, reducing THP-1 cell viability by over 50% at 100 µg/mL and inhibiting S. pyogenes with a 10.5 ± 1.1 mm zone. Nano-encapsulation enhanced both effects, reducing the IC₅₀ from 1.48 ± 0.03 µg/mL to 0.19 ± 0.01 µg/mL and increasing the bacterial inhibition zone to 15.6 ± 0.5 mm. n-PPE-EA induced apoptosis, cell cycle arrest, elevated catalase activity, and reduced malondialdehyde levels. It also downregulated BCL2, PI3K, and CDK8 expression.
conclusionThe nano-formulated PPE-EA demonstrated potent cytotoxic and antimicrobial activities, with enhanced efficacy attributed to improved bioavailability and modulation of apoptotic and cell cycle pathways. These findings support its potential as a multifunctional therapeutic agent in integrative cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.